Winning Stock Forecast: OPK Returns 30.46% in 7 Days, Fueled by Future Drug Expectations

“Scientific advancement should aim to affirm and to improve human life.”

– Nathan Deal

(Source: Cleveland Clinic)

OPKO Health, Inc. (NASDAQ: OPK) is a diversified healthcare company. Incorporated on November 18, 1991, the company’s segments include pharmaceutical, diagnostics, and corporate. The company’s pharmaceutical operations are in Chile, Mexico, Ireland, Israel, and Spain.

On July 5, I Know First Algorithm gave a bullish 7 day forecast for OPK. Since then, the stock has returned up to 30.46%.

Why did OPK see this sudden rise in

Read More

DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way

  The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.




  • Competitive Edge and Huge Market Potential from Heplisav-B®
  • Market Doubts about Trial Data of Immuno-Oncology Platform
  • Strong Cash Position from Debt Financing
  • Current I Know First Bullish Forecast For DVAX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.

  • Jay Luly, President and CEO

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development

Read More

Winning IMMU Stock Forecast: Progress in Commercialization of IMMU-132 Brings Great Growth Potential

“Based on the public data on IMMU-132 and available information regarding the Company’s pipeline, I believe the antibody-drug conjugates of Immunomedics have a high likelihood of improving the lives of countless patients with significant unmet medical needs…While the U.S. and global approval and commercialization of IMMU-132 for metastatic triple negative breast cancer are a key goal for me and my team, we simultaneously will be focused on developing IMMU-132 in multiple solid tumor indications, thereby laying the foundation to transform Immunomedics into a recognized leader

Read More

Winning ELGX Stock Forecast: Endologix Ends May With More Than 30% Gains

Our top-line performance during the first quarter reflects slightly better-than-expected growth in our OUS business driven by solid AFX growth in both the European and CAPLA markets…These accomplishments reinforce Endologix’s value proposition and our commitment to delivering the best products to physicians and patients around the globe.”

– Vaseem Mahbob, CFO of Endologix

(Source: PxHere)

Over the past 30 days, Endologix, Inc. (NASDAQ: ELGX) has been steadily climbing. Endologix, develops, produces

Read More

Quick Win By The Algorithm: DVAX Reaching New Heights

Quick Win by the Algorithm:

Read The Full Forecast

Quick win

Quick Win by the Algorithm: Biopharmaceutical Company IMMU a bullish winner

Quick Win By The Algorithm

Read The Full Forecast

quick win